The succinate dehydrogenase inhibition test for evaluating biopsy specimens and resected tumors of advanced gastric cancer

Surg Today. 1992;22(6):508-11. doi: 10.1007/BF00308895.

Abstract

An in vitro chemosensitivity study of both biopsy specimens and surgically resected tumors of advanced gastric cancer from 12 patients was evaluated using the succinate dehydrogenase inhibition (SDI) test. A decrease in succinate dehydrogenase (SD) activity as an indicator of chemosensitivity was determined using cisplatin (CDDP), etoposide (VP-16), and mitomycin C (MMC). In this study, 29 of a total 36 experiments were evaluable (80.6%) and significant correlations were found in all three of the antitumor drugs (P < 0.03). This finding suggests that the SDI test using biopsy specimens may prove valuable for assessing the preoperative chemosensitivity of advanced gastric cancer.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Biopsy
  • Cisplatin / therapeutic use
  • Drug Screening Assays, Antitumor*
  • Etoposide / therapeutic use
  • Female
  • Humans
  • Mitomycin / therapeutic use
  • Stomach Neoplasms / drug therapy
  • Stomach Neoplasms / enzymology*
  • Stomach Neoplasms / pathology
  • Stomach Neoplasms / surgery
  • Succinate Dehydrogenase / antagonists & inhibitors*

Substances

  • Mitomycin
  • Etoposide
  • Succinate Dehydrogenase
  • Cisplatin